Piper Sandler analyst Michael Lavery expects Cronos Group (CRON) to report "strong" sales growth, driven largely by the company's potential for large gains in U.S. CBD. Cronos has important relationships with U.S. cannabis retail operators that could provide turnkey access to shelf space once it becomes legal to enter the market, Lavery tells investors in a research note. The analyst also believes the company's partnership with Altria (MO) provides "important capital" and access into ~200,000 U.S. retail outlets, as well as regulatory and vapor product expertise. Lavery maintains a $12 price target and Overweight rating on the shares and believes Cronos' U.S. opportunities are likely underappreciated by the market.

In this edition of "Rising High," The Fly conducted an exclusive interview with Brendan Mitchel-Chesebro, industry analyst at BDSA, a Colorado-based cannabis market research and data analytics firm. Here are some... To see the rest of the story go to thefly.com. See Story Here